Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have a significant curative effect on EGFR-mutant lung cancer; however, patients treated with EGFR-TKIs eventually experience disease progression due to acquired drug resistance [2, 3]. The gene discussed is EGFR; the disease is lung carcinoma.